Picture loading failed.

Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-567-1mg 1mg 3090
GMP-Bios-ab-567-10mg 10mg Inquiry
GMP-Bios-ab-567-100mg 100mg Inquiry
GMP-Bios-ab-567-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody
INN Name Tezepelumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI Structure5j13:CB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAmgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia
Conditions Approvedna
Conditions ActiveAsthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease
Conditions Discontinuedna
Development Techna